The first ABO-incompatible kidney transplantion in Morocco has been successfully carried out following treatment with Glycosorb® ABO. The kidney transplant was performed from a related living donor - which is the primary application of Glycosorb® ABO - but the product is also increasingly used internationally to enable ABO-incompatible transplants of, for example, the liver and heart.

Morocco thus becomes the second country on the African continent to implement Glycosorb® ABO in clinical practice. The program was scientificatly supported by a renowned French kidney transplant specialist with extensive experience in ABO-incompatible transplants using Glycosorb® ABO.

In Morocco, transplant activity is on the rise. The introduction of ABO-incompatible kidney transplants from related living donors is expected to further increase the availability of organs for patients in need of transplantation.

For more information, please contact:
Johan Nilsson, CEO
Email: johan.nilsson@glycorex.com, Tel: +46 46 286 5230

Brief information about the company
Glycorex Transplantation AB (publ) is a global medical technology company headquartered in Sweden. The company has developed a unique medical technology (antigen-specific immunoadsorption) to specifically reduce blood group and autoantibodies in the blood.
The company's focus areas are within transplantation, blood transfusion, and autoimmune diseases. The company has sales in over 30 countries, with Europe as its largest market. Sales take place through own sales channels and in cooperation with distributors in selected markets. 
Product development and production takes place in the company's own facility in Lund, Sweden.
Glycosorb® ABO is one of the company's self-developed proprietary medical devices that is used to facilitate blood group-incompatible transplantation by specifically reducing anti-A/B antibodies in the organ recipient's plasma. Whilst primarily used to facilitate blood group incompatible kidney transplants, Glycosorb® ABO is also used in blood group incompatible liver-, heart-, lung-, and stem cell transplants. More than 60 scientific publications have been published in reputable medical journals, showing excellent short- and long-term outcomes of blood group incompatible transplants performed with Glycosorb® ABO. Glycosorb® ABO has been used in more than 7,000 transplants in over 30 countries. 
The company has also developed and CE-marked a medical device variant of Glycosorb® ABO that targets a different customer segment: transfusion clinics and blood centers. The product can help increase the availability of universal blood components and has been shown to be effective for the preparation of low-titer blood plasma, whole blood, and platelet concentrate.
The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis.
Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.